- 作者：Suguru Yamashita ; M.D.a ; Yoshihiro Sakamoto ; M.D. ; Ph.D.a ; Akio Saiura ; M.D. ; Ph.D.b ; Junji Yamamoto ; M.D. ; Ph.D.c ; Tomoo Kosuge ; M.D. ; Ph.D.d ; Taku Aoki ; M.D. ; Ph.D.a ; Yasuhiko Sugawara ; M.D. ; Ph.D.a ; Kiyoshi Hasegawa ; M.D. ; Ph.D.a ; Norihiro Kokudo ; M.D. ; Ph.D.a ; KOKUDO-2SU@h.u-tokyo.ac.jp" class="auth_mail
- 关键词：Pancreas-sparing duodenectomy ; Gastrointestinal stromal tumor ; Pancreaticoduodenectomy
- 刊名：The American Journal of Surgery
- 出版年：April, 2014
- 年：2014
- 卷：207
- 期：4
- 页码：578-583
- 全文大小：525 K
Background
Pancreas-sparing duodenectomy (PSD) is a promising alternative procedure to pancreaticoduodenectomy for the treatment of duodenal tumors with low-grade malignant behavior.Methods
Between March 2003 and September 2012, PSD was performed in 7 patients with a gastrointestinal stromal tumor (GIST) in the second (n = 5) or third (n = 2) portions of the duodenum. The short- and long-term outcomes of treatment were analyzed in all patients.
Results
The median blood loss was 160 mL, and the median operative time was 315 minutes. No pancreatic leakage or perioperative mortality occurred. Surgical margins were negative in all cases. All patients were alive at the median follow-up time of 42 months after PSD. The recurrence-free 5-year survival rate was 53% in all patients. Hepatic metastases developed in 2 of the 5 patients with high- or intermediate-grade risks at the time of diagnosis. Hepatic resection was performed, and imatinib mesylate was administered in the 2 cases.
Conclusions
Good short- and long-term outcomes and surgical curability were observed in patients treated with PSD for duodenal GIST.